Avita Medical Inc. (NASDAQ:RCEL) Given Average Rating of "Hold" by Analysts

Key Points

• Avita Medical Inc. has received a consensus rating of "Hold" from analysts, with five firms providing coverage that includes one sell, one hold, and three buy ratings.
• The stock's average price target is set at $11.60, but individual analysts have varying predictions, with targets ranging from $3.00 to $14.00.
• In its most recent earnings report, Avita Medical missed consensus estimates by posting a loss of $0.38 per share, compared to an expected loss of $0.26, alongside a significant decline in revenue.

Avita Medical Inc. (NASDAQ:RCEL - Get Free Report) has earned a consensus recommendation of "Hold" from the five ratings firms that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and three have given a buy recommendation to the company. The average 12 month price target among analysts that have covered the stock in the last year is $11.60.

Several equities research analysts have commented on RCEL shares. Lake Street Capital dropped their target price on Avita Medical from $14.00 to $8.00 and set a "buy" rating on the stock in a report on Monday, August 11th. D. Boral Capital reissued a "buy" rating and issued a $14.00 target price on shares of Avita Medical in a report on Monday, September 15th. BTIG Research downgraded Avita Medical from a "neutral" rating to a "sell" rating and set a $3.00 target price on the stock. in a report on Friday, August 8th. Finally, Wall Street Zen downgraded Avita Medical from a "hold" rating to a "sell" rating in a report on Saturday, August 9th.

Avita Medical Trading Down 2.4%

NASDAQ RCEL opened at $5.20 on Friday. The company has a quick ratio of 0.46, a current ratio of 0.58 and a debt-to-equity ratio of 9.39. Avita Medical has a twelve month low of $3.60 and a twelve month high of $14.16. The firm has a market capitalization of $138.42 million, a PE ratio of -2.64 and a beta of 1.58. The stock's 50 day moving average is $5.13 and its 200 day moving average is $6.52.

Avita Medical (NASDAQ:RCEL - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.12). Avita Medical had a negative net margin of 68.87% and a negative return on equity of 632.62%. The firm had revenue of $18.42 million for the quarter, compared to the consensus estimate of $34.27 million. Avita Medical has set its FY 2025 guidance at EPS. Research analysts forecast that Avita Medical will post -0.95 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Robert Mcnamara bought 10,000 shares of the company's stock in a transaction on Thursday, August 28th. The shares were acquired at an average cost of $4.50 per share, with a total value of $45,000.00. Following the completion of the acquisition, the director owned 86,771 shares of the company's stock, valued at $390,469.50. The trade was a 13.03% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders acquired 24,000 shares of company stock valued at $113,660 over the last 90 days. Insiders own 2.80% of the company's stock.

Institutional Investors Weigh In On Avita Medical

Several hedge funds have recently added to or reduced their stakes in RCEL. Ameriprise Financial Inc. lifted its holdings in shares of Avita Medical by 7.4% during the fourth quarter. Ameriprise Financial Inc. now owns 47,593 shares of the company's stock valued at $609,000 after purchasing an additional 3,269 shares in the last quarter. BNP Paribas Financial Markets bought a new position in shares of Avita Medical during the fourth quarter valued at $38,000. Bank of America Corp DE lifted its holdings in shares of Avita Medical by 16.2% during the fourth quarter. Bank of America Corp DE now owns 38,121 shares of the company's stock valued at $488,000 after purchasing an additional 5,324 shares in the last quarter. Deutsche Bank AG lifted its holdings in shares of Avita Medical by 78.9% during the fourth quarter. Deutsche Bank AG now owns 22,821 shares of the company's stock valued at $292,000 after purchasing an additional 10,063 shares in the last quarter. Finally, Millennium Management LLC bought a new position in shares of Avita Medical during the fourth quarter valued at $426,000. 27.66% of the stock is owned by institutional investors.

Avita Medical Company Profile

AVITA Medical, Inc, together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.